Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: A randomized clinical trial

JAMA

Volumn 311, Issue 16, 2014, Pages 1622-1631

  Ebinger, Martin ^a   Winter, Benjamin ^a   Wendt, Matthias ^a   Weber, Joachim E ^a   Waldschmidt, Carolin ^a   Rozanski, Michal ^a   Kunz, Alexander ^a   Koch, Peter ^a   Kellner, Philipp A ^b   Gierhake, Daniel ^a   Villringer, Kersten ^a   Fiebach, Jochen B ^a   Grittner, Ulrike ^a   Hartmann, Andreas ^c   Mackert, Bruno Marcel ^d   Endres, Matthias ^a,e,f   Audebert, Heinrich J ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b VIVANTES KLINIKUM IM FRIEDRICHSHAIN   (Germany)

^c Klinikum Frankfurt Oder   (Germany)

^d Vivantes Auguste Viktoria Klinikum   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f DZHK GERMAN CENTRE FOR CARDIOVASCULAR RESEARCH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

AGED; ALGORITHM; AMBULANCE; AMBULANCE BASED THROMBOLYSIS; AMBULANCE RESPONSE TIME; AMBULANCE TRANSPORTATION; ARTICLE; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; COMORBIDITY; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; EMERGENCY CARE; FEMALE; GERMANY; HEALTH CARE COST; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; POINT OF CARE TESTING; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RAPID RESPONSE TEAM; STROKE EMERGENCY MOBILE; TELEMEDICINE; TIME TO TREATMENT;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ALGORITHMS; AMBULANCES; BRAIN ISCHEMIA; EMERGENCY MEDICAL SERVICES; FEMALE; HUMANS; INTRACRANIAL HEMORRHAGES; MALE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; STROKE; SURVIVAL ANALYSIS; TELEMEDICINE; THROMBOLYTIC THERAPY; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84898776150     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.2850     Document Type: Article

References (24)

1. Murray CJ, Lopez AD. Measuring the global burden of disease. N Engl J Med. 2013;369(5):448-457.
2. Jauch EC, Saver JL, Adams HP Jr, et al American Heart Association Stroke Council; Council on Cardiovascular Nursing; Council on Peripheral Vascular Disease; Council on Clinical Cardiology. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870-947.
3. Tissue plasminogen activator for acute ischemic stroke: the National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. N Engl J Med. 1995;333(24):1581-1587.
4. Hacke W, Kaste M, Bluhmki E, et al ECASS Investigators. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317-1329.
5. Lees KR, Bluhmki E, von Kummer R, et al; ECASS, ATLANTIS, NINDS and EPITHET rt-PA Study Group. Time to treatment with intravenous alteplase and outcome in stroke: an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials. Lancet. 2010;375(9727):1695-1703.
6. Sandercock P, Wardlaw JM, Lindley RI, et al; IST-3 collaborative group. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third International Stroke Trial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352-2363.
7. Saver JL, Fonarow GC, Smith EE, et al. Time to treatment with intravenous tissue plasminogen activator and outcome from acute ischemic stroke. JAMA. 2013;309(23):2480-2488.
8. Fonarow GC, Smith EE, Saver JL, et al. Timeliness of tissue-type plasminogen activator therapy in acute ischemic stroke: patient characteristics, hospital factors, and outcomes associated with door-to-needle times within 60 minutes. Circulation. 2011;123(7):750-758.
9. Wahlgren N, Ahmed N, Dávalos A, et al; SITS investigators. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet. 2008;372(9646):1303-1309.
10. Fassbender K, Balucani C, Walter S, Levine SR, Haass A, Grotta J. Streamlining of prehospital stroke management: the golden hour. Lancet Neurol. 2013;12(6):585-596.
11. Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11(5):397-404.
12. Weber JE, Ebinger M, Rozanski M, et al STEMO-Consortium. Prehospital thrombolysis in acute stroke: results of the PHANTOM-S pilot study. Neurology. 2013;80(2):163-168.
13. Ebinger M, Rozanski M, Waldschmidt C, et al STEMO-Consortium. PHANTOM-S: the prehospital acute neurological therapy and optimization of medical care in stroke patients study. Int J Stroke. 2012;7(4):348-353.
14. Koennecke HC, Belz W, Berfelde D, et al Berlin Stroke Register Investigators. Factors influencing in-hospital mortality and morbidity in patients treated on a stroke unit. Neurology. 2011;77(10):965-972.
15. Koennecke HC, Walter G. Berliner Schlaganfallregister 2012 [in German]. http://www.aerztekammer-berlin.de/10arzt/40-Qualitaetssicherung/ 30-QM-Massnahmen-nach-Themen/30-BerlinerSchlaganfallregister/04-2012/ BSR-Gesamtbericht-2012.pdf. Accessed April 1, 2014.
16. Krebes S, Ebinger M, Baumann AM, et al. Development and validation of a dispatcher identification algorithm for stroke emergencies. Stroke. 2012;43(3):776-781.
17. European Stroke Organisation. http://www.eso-stroke.org. Accessed April 1, 2014.
18. Wardlaw JM, Murray V, Berge E, et al. Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysis. Lancet. 2012;379(9834):2364-2372.
19. Schwamm LH, Starkman S. Have CT, will travel: to boldly go where no scan has gone before. Neurology. 2013;80(2):130-131.
20. Audebert HJ, Saver JL, Starkman S, Lees KR, Endres M. Prehospital stroke care: new prospects for treatment and clinical research. Neurology. 2013;81(5):501-508.
21. Lansberg MG, Schrooten M, Bluhmki E, Thijs VN, Saver JL. Treatment time-specific number needed to treat estimates for tissue plasminogen activator therapy in acute stroke based on shifts over the entire range of the modified Rankin Scale. Stroke. 2009;40(6):2079-2084.
22. Wahlgren N, Ahmed N, Dávalos A, et al; SITS-MOST investigators. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet. 2007;369(9558):275-282. (Pubitemid 46138121)
23. Meretoja A, Strbian D, Mustanoja S, Tatlisumak T, Lindsberg PJ, Kaste M. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306-313.
24. Köhrmann M, Schellinger PD, Breuer L, et al. Avoiding in hospital delays and eliminating the three-hour effect in thrombolysis for stroke. Int J Stroke. 2011;6(6):493-497.